** Citi upgrades Healius' HLS.AX rating to "neutral" from "sell" on recent share price decline, the sale of co's unit Lumus Imaging and cost base of its pathology segment reflecting its true business as usual costs
** Brokerage trims price target for co to A$1.05 from A$1.5 to reflect Lumus sale in its forecasts
** Citi forecasts HLS to distribute special dividend of 40 Australian cents/share from sale of Lumus
** The Aussie healthcare firm on Friday shared positive outlook for its pathology business, foreacsting strong growth in 2H
** HLS down ~19.9% YTD as of last close, underperforming against a 3.4% gain on the ASX Health Care index .AXHJ
($1 = 1.5319 Australian dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。